Zobrazeno 1 - 10 of 578 pro vyhledávání: '"Mouritzen, U."'
2
Akademický článek
Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes.
Autor: Cliff CL; Joseph Banks Laboratories, School of Life, Sciences University of Lincoln, Lincoln LN6 7DL, UK., Williams BM; Joseph Banks Laboratories, School of Life, Sciences University of Lincoln, Lincoln LN6 7DL, UK., Chadjichristos CE; National Institutes for Health and Medical Research, UMR-S1155, Batiment Recherche, Tenon Hospital, 4 Rue de la Chine, 75020 Paris, France., Mouritzen U; Ciana Therapeutics, Ole Maaloes Vej 3, 2200 Copenhagen N, Denmark., Squires PE; Joseph Banks Laboratories, School of Life, Sciences University of Lincoln, Lincoln LN6 7DL, UK., Hills CE; Joseph Banks Laboratories, School of Life, Sciences University of Lincoln, Lincoln LN6 7DL, UK.
Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Jan 06; Vol. 23 (2). Date of Electronic Publication: 2022 Jan 06.
Zobrazit plný text záznamu
3
Akademický článek
Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney.
Autor: Squires PE; School of Life Sciences, Joseph Banks Laboratories, University of Lincoln, Lincoln LN6 7DL, UK., Price GW; School of Life Sciences, Joseph Banks Laboratories, University of Lincoln, Lincoln LN6 7DL, UK., Mouritzen U; Ciana Therapeutics, Ved Hegnet 2, 2960 Rungsted Kyst, Copenhagen, Denmark., Potter JA; School of Life Sciences, Joseph Banks Laboratories, University of Lincoln, Lincoln LN6 7DL, UK., Williams BM; School of Life Sciences, Joseph Banks Laboratories, University of Lincoln, Lincoln LN6 7DL, UK., Hills CE; School of Life Sciences, Joseph Banks Laboratories, University of Lincoln, Lincoln LN6 7DL, UK.
Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2021 Mar 10; Vol. 22 (6). Date of Electronic Publication: 2021 Mar 10.
Zobrazit plný text záznamu
4
Akademický článek
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.
Autor: Naimi RM; Department of Medical Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark. Electronic address: rahim.mohammad.naimi@regionh.dk., Hvistendahl M; Department of Medical Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark., Enevoldsen LH; Department of Clinical Physiology, Nuclear Medicine, and PET, Rigshospitalet, Copenhagen, Denmark., Madsen JL; Department of Clinical Physiology and Nuclear Medicine, Centre for Functional and Diagnostic Imaging and Research, Hvidovre Hospital, Hvidovre, Denmark., Fuglsang S; Department of Clinical Physiology and Nuclear Medicine, Centre for Functional and Diagnostic Imaging and Research, Hvidovre Hospital, Hvidovre, Denmark., Poulsen SS; Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark., Kissow H; Novo Nordisk Foundation Centre of Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Pedersen J; Novo Nordisk Foundation Centre of Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Nerup N; Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark., Ambrus R; Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark., Achiam MP; Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark., Svendsen LB; Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark., Holst JJ; Novo Nordisk Foundation Centre of Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Hartmann B; Novo Nordisk Foundation Centre of Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Hansen SH; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark., Dragsted LO; Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark., Steensberg A; Research and Development, Zealand Pharma, Glostrup, Denmark., Mouritzen U; Research and Development, Zealand Pharma, Glostrup, Denmark., Hansen MB; Research and Development, Zealand Pharma, Glostrup, Denmark., Jeppesen PB; Department of Medical Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark.
Publikováno v: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2019 May; Vol. 4 (5), pp. 354-363. Date of Electronic Publication: 2019 Mar 15.
Zobrazit plný text záznamu
5
Akademický článek
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
Autor: Hövelmann U; Profil, Neuss, Germany., Olsen MB; Zealand Pharma A/S, Glostrup, Denmark., Mouritzen U; Zealand Pharma A/S, Glostrup, Denmark., Lamers D; Profil, Neuss, Germany., Kronshage B; Profil, Neuss, Germany., Heise T; Profil, Neuss, Germany.
Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Mar; Vol. 21 (3), pp. 601-610. Date of Electronic Publication: 2018 Nov 28.
Zobrazit plný text záznamu
7
Akademický článek
Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial.
Autor: Engstrøm T; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Department of Cardiology, University of Lund, Lund, Sweden., Nepper-Christensen L; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Helqvist S; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Kløvgaard L; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Holmvang L; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Jørgensen E; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Pedersen F; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Saunamaki K; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Tilsted HH; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Steensberg A; Zealand Pharma A/S, Copenhagen, Denmark., Fabricius S; Zealand Pharma A/S, Copenhagen, Denmark., Mouritzen U; Zealand Pharma A/S, Copenhagen, Denmark., Vejlstrup N; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Ahtarovski KA; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Göransson C; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Bertelsen L; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Kyhl K; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Olivecrona G; Department of Cardiology, University of Lund, Lund, Sweden., Kelbæk H; Department of Cardiology, Zealand University Hospital, Roskilde, Denmark., Lassen JF; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Køber L; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Lønborg J; Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Publikováno v: Heart (British Cardiac Society) [Heart] 2018 Oct; Vol. 104 (19), pp. 1593-1599. Date of Electronic Publication: 2018 Mar 30.
Zobrazit plný text záznamu
8
Akademický článek
Inhibition of Cx43 gap junction uncoupling prevents high glucose-induced apoptosis and reduces excess cell monolayer permeability in retinal vascular endothelial cells.
Autor: Kim D; Departments of Medicine and Ophthalmology, Boston University School of Medicine, Boston, MA, USA., Mouritzen U; Department of Clinical Development, Zealand Pharma A/S, Glostrup, Denmark., Larsen BD; Medicinal Chemistry, Zealand Pharma A/S, Glostrup, Denmark., Roy S; Departments of Medicine and Ophthalmology, Boston University School of Medicine, Boston, MA, USA. Electronic address: sayon@bu.edu.
Publikováno v: Experimental eye research [Exp Eye Res] 2018 Aug; Vol. 173, pp. 85-90. Date of Electronic Publication: 2018 May 09.
Zobrazit plný text záznamu
9
Akademický článek
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
Autor: Hövelmann U; Profil, Neuss, Germany ulrike.hoevelmann@profil.com., Bysted BV; Zealand Pharma A/S, Glostrup, Denmark., Mouritzen U; Zealand Pharma A/S, Glostrup, Denmark., Macchi F; Zealand Pharma A/S, Glostrup, Denmark., Lamers D; Profil, Neuss, Germany., Kronshage B; Profil, Neuss, Germany., Møller DV; Zealand Pharma A/S, Glostrup, Denmark., Heise T; Profil, Neuss, Germany.
Publikováno v: Diabetes care [Diabetes Care] 2018 Mar; Vol. 41 (3), pp. 531-537. Date of Electronic Publication: 2017 Dec 22.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje